Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-one ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $36.90.

Several research analysts have recently commented on NTLA shares. Barclays lowered their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Wells Fargo & Company dropped their price target on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Guggenheim dropped their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research report on Monday. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research report on Monday, March 3rd.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics in the 4th quarter worth about $25,000. Sterling Capital Management LLC lifted its stake in Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after buying an additional 2,867 shares during the period. Harbour Investments Inc. boosted its holdings in shares of Intellia Therapeutics by 76.7% during the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after buying an additional 2,264 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $40,000. Finally, Resona Asset Management Co. Ltd. acquired a new position in shares of Intellia Therapeutics during the 4th quarter valued at $43,000. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Trading Up 5.3%

Shares of NASDAQ:NTLA traded up $0.43 during trading on Friday, reaching $8.55. 3,872,360 shares of the stock were exchanged, compared to its average volume of 2,481,680. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.18. The stock has a 50-day moving average price of $8.13 and a 200-day moving average price of $10.97. The firm has a market cap of $885.63 million, a PE ratio of -1.57 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the previous year, the business earned ($1.12) EPS. The firm's quarterly revenue was down 42.6% on a year-over-year basis. On average, sell-side analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.